As a CenSSIS partner, ART will have complete access to, and the ability to leverage, all core research results from CenSSIS thus accelerating ART's development process. ART will play a key role in supporting the basic research and in guiding CenSSIS researchers toward improved medical imaging technologies. Furthermore, as a member of the CenSSIS Industrial Advisory Board, ART will counsel CenSSIS on the strategic direction of its research and educational programs. ART is the first international business to join the network of CenSSIS business partners, which include Raytheon, Mercury Computer Systems, The MathWorks and Lockheed Martin.
"ART's optical imaging technology will be the cornerstone in the validation of the sophisticated physics-based information extraction techniques which are at the heart of the advances being made at CenSSIS", commented Dr. Eric Miller, Associate Professor of electrical and computer engineering at Northeastern University. "Close collaboration between researchers at ART and CenSSIS will provide the type of mutual feedback required to advance the state of the art in the area of tomographic imaging while yielding tangible results that have the potential for having a positive impact on a crucial societal problem: the fight against breast cancer", added Dr. Miller.
"ART is very pleased to be collaborating with CenSSIS", stated Richard Boudreault, Vice President, Research and Development of ART. "As a CenSSIS partner, ART will have access to core intellectual property and will benefit from a most stimulating and dynamic scientific network", added Mr. Boudreault. "This will allow us to improve on biomedical image delivery through innovative algorithms".
Headquartered in Boston at Northeastern University, CenSSIS is a National Science Foundation Cross-disciplinary Engineering Research Center. It seeks to revolutionize the ability to detect and image objects or conditions that are underground, underwater, embedded within cells or inside the human body. The CenSSIS multi-disciplinary approach combines expertise in wave physics, sensor engineering, image processing and inverse scattering with rigorous performance testing to create new sensing system prototypes.
CenSISS has core academic partnerships with Boston University (BU), Rensselaer Polytechnic Institute (RPI) and University of Puerto Rico at Mayagüez (UPRM). The Center's core strategic affiliates include Lawrence Livermore National Laboratory (LLNL), Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH) and Woods Hole Oceanographic Institution (WHOI). For more information about CenSSIS, go to www.censsis.neu.edu.
ART Advanced Research Technologies Inc. is a North American company that is involved in the research, design, development, and marketing of optical and infrared imaging technologies used in the detection of anomalies in the medical sector and the electronics industry. ART is in the process of bringing to market an optical imaging device to detect and diagnose breast anomalies. The device, known as SoftScan®, represents an innovative imaging solution for the detection of breast lesions without the adverse consequences associated with traditional technology. SoftScan® uses the time domain technique in optical imaging, which generates the most information possible about tissue. ART is also working on the development of a novel and proprietary molecular imaging technology, designed to characterize and measure cellular and molecular processes and pathways. With respect to the electronics industry, ART is currently commercializing its ISIS® products, which are based on infrared verification imaging technology, and are used to detect defects in printed circuit board assemblies. ART has been listed on the Toronto Stock Exchange since June 29, 2000 (TSE: "ARA"). For more information about ART go to www.art.ca.
ART's SoftScan® optical breast imaging device produces a functional image that can depict blood volumes and blood oxygen content simultaneously. With this combination of images, the SoftScan® device may permit the detection of anomalies in the breast that previously went undetected and may, in turn, be better able to determine whether a tumor is malignant or benign.